Opinion|Videos|October 14, 2024
Exploring the Kidney-CHAMP Study
Key Takeaways
- The trial focused on improving cardiovascular risk management in type 2 diabetes through a coordinated care model involving healthcare systems.
- Interventions included educational sessions, feedback, and support for healthcare providers to enhance adherence to guideline-directed medical therapy.
A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Tell us about Kidney-CHAMP study.
- What were the objectives of Kidney-CHAMP and how was the study designed?
- What interventions were provided?
- What were the results of the study?
- What are future opportunities to improve CRM care based on this study?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
5